

Jose Luis Calleja-Panero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3480219/publications.pdf>

Version: 2024-02-01

259
papers

13,634
citations

26630

56
h-index

22832

112
g-index

275
all docs

275
docs citations

275
times ranked

11066
citing authors

#	ARTICLE	IF	CITATIONS
1	Boceprevir for Untreated Chronic HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2011, 364, 1195-1206.	27.0	2,352
2	Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. <i>Journal of Hepatology</i> , 2016, 65, 719-726.	3.7	883
3	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases</i> , 2016, 16, 685-697.	9.1	402
4	Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. <i>Hepatology</i> , 2003, 37, 208-217.	7.3	381
5	β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet</i> , 2019, 393, 1597-1608.	13.7	375
6	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. <i>Journal of Viral Hepatitis</i> , 2014, 21, 34-59.	2.0	372
7	PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. <i>Journal of Hepatology</i> , 2016, 64, 800-806.	3.7	358
8	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
9	Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. <i>Gastroenterology</i> , 2004, 127, 1347-1355.	1.3	322
10	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017, 66, 1444-1453.	7.3	239
11	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. <i>Gastroenterology</i> , 2016, 150, 1160-1170.e3.	1.3	232
12	Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. <i>Hepatology</i> , 2017, 65, 1293-1305.	7.3	225
13	Historical epidemiology of hepatitis C virus (<sc>HCV</sc>) in selected countries. <i>Journal of Viral Hepatitis</i> , 2014, 21, 5-33.	2.0	211
14	Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. <i>Gastroenterology</i> , 2017, 153, 1273-1283.e1.	1.3	210
15	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	8.1	208
16	Portal Hypertension-Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagulation. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1412-1417.	4.4	175
17	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 154, 1694-1705.e4.	1.3	162
18	Strategies to manage hepatitis <sc>C</sc> virus (<sc>HCV</sc>) disease burden. <i>Journal of Viral Hepatitis</i> , 2014, 21, 60-89.	2.0	161

#	ARTICLE	IF	CITATIONS
19	Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. <i>Journal of Hepatology</i> , 2017, 66, 1138-1148.	3.7	159
20	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020, 73, 1368-1378.	3.7	158
21	Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: A double-blind RCT. <i>Hepatology</i> , 2003, 37, 1260-1266.	7.3	149
22	Preemptive TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , 2019, 69, 282-293.	7.3	144
23	Visceral leishmaniasis in patients infected with human immunodeficiency virus. <i>Journal of Infection</i> , 1990, 21, 261-270.	3.3	143
24	Development of hyperdynamic circulation and response to β -blockers in compensated cirrhosis with portal hypertension. <i>Hepatology</i> , 2016, 63, 197-206.	7.3	143
25	Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. <i>Hepatology</i> , 2009, 50, 1702-1708.	7.3	136
26	Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. <i>Journal of Hepatology</i> , 2015, 63, 564-572.	3.7	132
27	Double-guidewire technique for difficult bile duct cannulation: a multicenter randomized, controlled trial. <i>Gastrointestinal Endoscopy</i> , 2009, 70, 700-709.	1.0	125
28	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	3.7	112
29	Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. <i>Gastroenterology</i> , 1998, 115, 116-123.	1.3	108
30	Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. <i>Journal of Viral Hepatitis</i> , 2017, 24, 823-831.	2.0	107
31	Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. <i>International Journal of Colorectal Disease</i> , 2016, 31, 543-551.	2.2	106
32	Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , 2011, 54, 1114-1122.	3.7	105
33	Development and Validation of Hepamet Fibrosis Scoring System—A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	4.4	104
34	Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. <i>Journal of Hepatology</i> , 2020, 73, 1415-1424.	3.7	104
35	Isosorbide Mononitrate in the Prevention of First Variceal Bleed in Patients Who Cannot Receive β -blockers. <i>Gastroenterology</i> , 2001, 121, 908-914.	1.3	103
36	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1140-1150.	3.7	97

#	ARTICLE	IF	CITATIONS
37	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. <i>Gastroenterology</i> , 2021, 160, 193-205.e10.	1.3	97
38	Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive β -blockers. <i>Gastroenterology</i> , 2001, 121, 908-914.	1.3	94
39	Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. <i>Journal of Hepatology</i> , 2019, 71, 660-665.	3.7	93
40	Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 62, 32-36.	5.8	92
41	Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2017, 66, 718-723.	3.7	90
42	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , 2018, 68, 1129-1136.	3.7	88
43	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa registry. <i>Hepatology</i> , 2017, 65, 1810-1822.	7.3	78
44	Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. <i>Gastroenterology</i> , 2018, 155, 1120-1127.e4.	1.3	76
45	Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. <i>Journal of Hepatology</i> , 1994, 21, 88-94.	3.7	75
46	Sustained response to interferon- α or to interferon- α plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1179-1186.	3.7	75
47	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 1088-1096.	3.7	75
48	Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. <i>American Journal of Gastroenterology</i> , 2018, 113, 1639-1648.	0.4	72
49	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1260-1270.	3.7	70
50	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, 1037-1045.	3.7	69
51	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , 2019, 70, 874-884.	3.7	67
52	Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. <i>Journal of Hepatology</i> , 2019, 71, 666-672.	3.7	67
53	Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. <i>Antiviral Therapy</i> , 2009, 14, 23-32.	1.0	66
54	Hemodynamic effects of α -adrenergic blockade with prazosin in cirrhotic patients with portal hypertension. <i>Hepatology</i> , 1994, 20, 611-617.	7.3	64

#	ARTICLE	IF	CITATIONS
55	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 593-604.	12.1	62
56	Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1846-1853.e1.	4.4	60
57	Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. <i>Journal of Hepatology</i> , 1996, 24, 308-312.	3.7	59
58	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020, 73, 17-25.	3.7	59
59	Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 784-793.	2.3	55
60	Validation of noninvasive methods to predict the presence of gastroesophageal varices in a cohort of patients with compensated advanced chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1867-1872.	2.8	54
61	O68 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY. <i>Journal of Hepatology</i> , 2014, 60, S28.	3.7	52
62	Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection: A Randomized Trial. <i>Gastroenterology</i> , 2013, 145, 1035-1044.e5.	1.3	51
63	Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. <i>Journal of Viral Hepatitis</i> , 2017, 24, 936-943.	2.0	48
64	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2022, 76, 311-318.	3.7	48
65	Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. <i>PLoS ONE</i> , 2017, 12, e0184550.	2.5	45
66	Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19. <i>Journal of Infectious Diseases</i> , 2020, 222, 726-733.	4.0	43
67	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020, 174, 104694.	4.1	39
68	Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain. <i>Journal of Viral Hepatitis</i> , 2020, 27, 360-370.	2.0	39
69	Adding Branched-Chain Amino Acids to an Enhanced Standard-of-Care Treatment Improves Muscle Mass of Cirrhotic Patients With Sarcopenia: A Placebo-Controlled Trial. <i>American Journal of Gastroenterology</i> , 2021, 116, 2241-2249.	0.4	39
70	<i>Helicobacter pylori</i> eradication for the treatment of low-grade gastric MALT lymphoma: Follow-up together with sequential molecular studies. <i>Annals of Oncology</i> , 1997, 8, S37-S39.	1.2	38
71	Reactivation of Herpesvirus in Patients With Hepatitis C Treated With Direct-Acting Antiviral Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1662-1666.e1.	4.4	38
72	Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 589-599.	3.7	36

#	ARTICLE	IF	CITATIONS
73	Management of anemia induced by triple therapy in patients with chronic hepatitis C: Challenges, opportunities and recommendations. <i>Journal of Hepatology</i> , 2013, 59, 1323-1330.	3.7	35
74	Probiotic supplementation with <i>Lactobacillus plantarum</i> and <i>Pediococcus acidilactici</i> for <i>Helicobacter pylori</i> therapy: A randomized, double-blind, placebo-controlled trial. <i>Helicobacter</i> , 2018, 23, e12529.	3.5	34
75	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016, 6, 31421.	3.3	33
76	Hypersensitivity pneumonitis due to an ultrasonic humidifier. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1998, 53, 210-212.	5.7	32
77	Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia. <i>Technology and Health Care</i> , 2016, 24, 111-120.	1.2	31
78	Accuracy of portal and forearm blood flow measurements in the assessment of the portal pressure response to propranolol. <i>Journal of Hepatology</i> , 1997, 27, 496-504.	3.7	30
79	LP13 : Effect of long term viral suppression with sofosbuvir + ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension. <i>Journal of Hepatology</i> , 2015, 62, S269-S270.	3.7	30
80	Simeprevir in combination with sofosbuvir in treatment-naïve and experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO). <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 468-475.	3.7	30
81	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 12-19.	2.0	28
82	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021, 75, 342-350.	3.7	28
83	Changes in gastrin and serum pepsinogens in monitoring of <i>Helicobacter pylori</i> response to therapy. <i>Digestive Diseases and Sciences</i> , 1997, 42, 1734-1740.	2.3	26
84	Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, 1400-1409.	0.4	26
85	Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 779-789.	2.2	25
86	Eliminación de la hepatitis C. Documento de posicionamiento de la Asociación Española para el Estudio del Hígado (AEEH). <i>Gastroenterología Y Hepatología</i> , 2019, 42, 579-592.	0.5	25
87	Eliminación de la hepatitis C en España: adaptación de un modelo matemático de salud pública partiendo del plan estratégico para el abordaje de la hepatitis C en el Sistema Nacional de Salud. <i>Medicina Clínica</i> , 2017, 148, 277-282.	0.6	24
88	Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes. <i>Liver International</i> , 2022, 42, 984-994.	3.9	24
89	Prevalence of viral hepatitis (B and C) serological markers in healthy working population. <i>Revista Española De Enfermedades Digestivas</i> , 2013, 105, 249-254.	0.3	23
90	Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis. <i>Clinical Infectious Diseases</i> , 2020, 71, 2726-2729.	5.8	23

#	ARTICLE	IF	CITATIONS
91	Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 406-414.e7.	4.4	23
92	Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70 Hepatitis C. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4727-4735.	3.2	22
93	Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 945-949.e1.	4.4	22
94	Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2017, 24, 226-237.	2.0	22
95	Liver transplantation for autoimmune hepatitis: fulminant versus chronic hepatitis presentation. <i>Transplantation Proceedings</i> , 2003, 35, 1857-1858.	0.6	20
96	Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic <sc>HCV</sc> infection: Results from the Spanish <sc>HEPA</sc> real world cohort. <i>Journal of Viral Hepatitis</i> , 2019, 26, 55-64.	2.0	20
97	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. <i>European Journal of Radiology</i> , 2021, 135, 109484.	2.6	20
98	Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 409-419.	3.7	19
99	El diagnÃ³stico de la infecciÃ³n por el virus de la hepatitis C en EspaÃ±a: una oportunidad para mejorar. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2019, 37, 231-238.	0.5	19
100	Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 527-535.e6.	4.4	19
101	Massive impact of coronavirus disease 2019 pandemic on gastroenterology and hepatology departments and doctors in Spain. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1627-1633.	2.8	19
102	Impact of Nocturnal Heartburn on Quality of Life, Sleep, and Productivity: The SINERGE Study. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2858-2865.	2.3	18
103	Autonomic neuropathy is associated with hemodynamic instability during human liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 1866-1868.	0.6	17
104	The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease. <i>BMC Infectious Diseases</i> , 2017, 17, 45.	2.9	17
105	Hepatitis C prevalence among the migrant population in Spain: A systematic review and meta-analysis. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2019, 37, 222-230.	0.5	16
106	Portal vein filling: an unusual complication of needle-knife sphincterotomy. <i>Endoscopy</i> , 2007, 39, E245-E245.	1.8	15
107	Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. <i>Journal of Hepatology</i> , 2018, 68, 940-948.	3.7	15
108	GuÃa de tratamiento de la infecciÃ³n por virus de la hepatitis C. AsociaciÃ³n EspaÃ±ola para el Estudio del HÃgado (AEEH). <i>GastroenterologÃa Y HepatologÃa</i> , 2018, 41, 597-608.	0.5	15

#	ARTICLE	IF	CITATIONS
109	Diagnóstico en un solo paso de la hepatitis C en 2019: una realidad en España. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2021, 39, 119-126.	0.5	15
110	Autonomic neuropathy in end-stage cirrhotic patients and evolution after liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 1834-1835.	0.6	13
111	O167 ADDITION OF SIMVASTATIN TO STANDARD TREATMENT IMPROVES SURVIVAL AFTER VARICEAL BLEEDING IN PATIENTS WITH CIRRHOSIS. A DOUBLE-BLIND RANDOMIZED TRIAL (NCT01095185). <i>Journal of Hepatology</i> , 2014, 60, S525.	3.7	13
112	Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. <i>Liver International</i> , 2015, 35, 90-100.	3.9	13
113	Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review. <i>Scientific Reports</i> , 2021, 11, 24133.	3.3	13
114	Selective impairment of endothelium-mediated vasodilation in liver transplant recipients with cyclosporin A-induced hypertension. <i>Hepatology</i> , 1998, 27, 332-338.	7.3	12
115	<i>Helicobacter pylori</i> Infection in Patients with Erosive Esophagitis Is Associated with Rapid Heartburn Relief and Lack of Relapse After Treatment with Pantoprazole. <i>Digestive Diseases and Sciences</i> , 2005, 50, 432-439.	2.3	12
116	[586] SAFETY, PHARMACOKINETICS AND ANTIVIRAL EFFECT OF BILB1941, A NOVEL HCV RNA POLYMERASE INHIBITOR, AFTER 5 DAYS ORAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2007, 46, S222.	3.7	12
117	The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, 311-316.	3.7	12
118	Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 267-271.	1.6	12
119	High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. <i>United European Gastroenterology Journal</i> , 2021, 9, 892-902.	3.8	12
120	Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1635-1642.	2.0	12
121	Prevalence and outcome of portal thrombosis in a cohort of cirrhotic patients undergoing liver transplantation. <i>Revista Espanola De Enfermedades Digestivas</i> , 2016, 108, 716-720.	0.3	12
122	Hepatitis B reactivation and current clinical impact. <i>Revista Espanola De Enfermedades Digestivas</i> , 2010, 102, 542-52.	0.3	12
123	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 862-873.	0.3	12
124	Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 6658-6668.	3.3	12
125	Primary liposarcoma of the lung in a young woman.. <i>Thorax</i> , 1990, 45, 298-299.	5.6	11
126	Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. <i>Journal of Clinical Virology</i> , 2015, 68, 56-60.	3.1	11

#	ARTICLE	IF	CITATIONS
127	Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCVâ€œcoinfected and HCVâ€œmonoinfected patients. <i>Liver International</i> , 2020, 40, 2215-2227.	3.9	11
128	Outcomes of peptic ulcer bleeding following treatment with proton pump inhibitors in routine clinical practice: 935 patients with high- or low-risk stigmata. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1181-1190.	1.5	10
129	Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection. <i>Genes and Immunity</i> , 2015, 16, 297-300.	4.1	10
130	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , 2017, 37, 1823-1832.	3.9	10
131	Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase <sc>II SATURN</sc> study. <i>Transplant Infectious Disease</i> , 2017, 19, e12696.	1.7	10
132	Efficacy and safety of a twoâ€œdrug directâ€œacting antiviral agent regimen ruzasvir 180Âmg and uprifosbuvir 450Âmg for 12Âweeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1127-1138.	2.0	10
133	Undetectable <sc>HCV</sc>â€œRNA</sc> at treatmentâ€œweek 8 results in highâ€œsustained virological response in <sc>HCV</sc> G1 treatmentâ€œexperienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , 2015, 22, 469-480.	2.0	9
134	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1343-1353.e16.	4.4	9
135	The efficiency of several one-step testing strategies for the diagnosis of hepatitis C. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 111, 10-16.	0.3	9
136	Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 131-143.	3.7	9
137	Localized lymphadenitis due to leishmania. Diagnosis by fine needle aspiration cytology.. <i>Postgraduate Medical Journal</i> , 1990, 66, 326-326.	1.8	8
138	Selective Biliary Cannulation Using Pancreatic Guide-Wire Placement: Further Evidence Needed to Support the Use of an Already Known Technique. <i>Endoscopy</i> , 2004, 36, 457.	1.8	8
139	A randomized trial to compare the efficacy and tolerability of sodium picosulfate-magnesium citrate solution vs. 4ÂL polyethylene glycol solution as a bowel preparation for colonoscopy. <i>International Journal of Colorectal Disease</i> , 2015, 30, 1407-1416.	2.2	8
140	Treatment of Hepatitis C Virus in Patients with Advanced Cirrhosis: Always Justified? Analysis of the Hepa-C Registry. <i>Journal of Hepatology</i> , 2016, 64, S133.	3.7	8
141	Severe splenic rupture after colorectal endoscopic submucosal dissection. <i>World Journal of Gastroenterology</i> , 2014, 20, 9618-9620.	3.3	8
142	Tenofovir <i>vs</i> lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. <i>World Journal of Gastroenterology</i> , 2017, 23, 7459-7469.	3.3	8
143	Leishmaniasis masking tuberculosis. <i>Lancet, The</i> , 1990, 335, 299-300.	13.7	7
144	Liver transplantation for fulminant and subfulminant hepatic failure. <i>Transplantation Proceedings</i> , 2003, 35, 1855-1856.	0.6	7

#	ARTICLE	IF	CITATIONS
145	A survey of chronic hepatitis B patient management practices in the European Union. <i>Journal of Viral Hepatitis</i> , 2010, 17, no-no.	2.0	7
146	Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015, 21, 5421.	3.3	7
147	Visceral fat is associated with cirrhotic portal vein thrombosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 1017-1022.	3.0	7
148	Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 397-411.	0.3	7
149	Meta-analysis: pegylated interferon α achieves higher early virological responses than β in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 1065-1073.	3.7	6
150	Effect of proton pump inhibitors on the outcomes of peptic ulcer bleeding: comparison of event rates in routine clinical practice and a clinical trial. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 285-294.	1.5	6
151	Successful Continuation of HCV Treatment After Liver Transplantation. <i>Transplantation</i> , 2017, 101, 1009-1012.	1.0	6
152	Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System. <i>Medicina Clínica (English)</i> Tj ETQq0 0 0 rgBT.2 Overlock 10 Tf 50	0.2	6
153	Tacrolimus as an Effective and Durable Second-Line Treatment for Chronic Autoimmune Hepatitis: A Multicentric Study. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2826-2832.	2.3	6
154	Update on epidemiology of hepatitis B in a low-endemic European country: There is still much to do. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1261-1265.	2.0	6
155	Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020, 43, 332-347.	0.1	6
156	Idiopathic portal hypertension regarding thiopurine treatment in patients with inflammatory bowel disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2015, 108, 79-83.	0.3	6
157	1137 THE HLA CLASS I B*1801 ALLELE INFLUENCES HEPATOCELLULAR EXPRESSION OF AMOXICILLIN-CLAVULANATE LIVER DAMAGE AND OUTCOME IN SPANISH PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S439.	3.7	5
158	P1058 LONG-TERM EFFICACY OF TENOFOVIR IN PREVIOUSLY TREATED AND NAIVE PATIENTS. RESULTS FROM THE SPANISH CHRONIC HEPATITIS B REGISTRY (CIBERHEP). <i>Journal of Hepatology</i> , 2014, 60, S429.	3.7	5
159	Arteriportal fistula, a rare cause of presinusoidal portal hypertension. <i>Gastroenterología Y Hepatología</i> , 2016, 39, 43-45.	0.5	5
160	FRI-225-Universal access to direct-acting antivirals treatment is not not enough to prevent late stage presentation of hepatitis C infection. <i>Journal of Hepatology</i> , 2019, 70, e493-e494.	3.7	5
161	Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort. <i>Liver International</i> , 2019, 39, 90-97.	3.9	5
162	Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury. <i>JHEP Reports</i> , 2021, 3, 100276.	4.9	5

#	ARTICLE	IF	CITATIONS
163	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100290.	4.9	5
164	Non-malignant portal vein thrombosis in a cohort of cirrhotic patients: Incidence and risk factors. <i>Hepatology Research</i> , 2021, 51, 1064-1072.	3.4	5
165	Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4885.	2.4	5
166	Sclerotherapy in acute variceal bleeding. <i>Gastrointestinal Endoscopy</i> , 1999, 49, 140-141.	1.0	4
167	1001 INTERIM ANALYSIS FROM TRIC-1 A STUDY OF METFORMIN WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAIVE GENOTYPE 1 CHRONIC HEPATITIS C WITH INSULIN RESISTANCE. <i>Journal of Hepatology</i> , 2008, 48, S375.	3.7	4
168	Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 46-54.	1.6	4
169	Efficacy and Tolerability of Interferon-Free Antiviral Therapy in Kidney Transplant (KT) Recipients with Chronic Hepatitis C: Real-Life Data from the Spanish National Registry (HEPA-C). <i>Journal of Hepatology</i> , 2016, 64, S793-S794.	3.7	4
170	Preventing decompensation of cirrhosis with clinically significant portal hypertension and without high-risk varices: a new indication for non-selective beta-blockers (NSBB). <i>Journal of Hepatology</i> , 2017, 66, S97-S98.	3.7	4
171	HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz214.	0.9	4
172	Definition of the profiles of hepatitis C virus patients based on the identification of risky practices in Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 731-737.	0.3	4
173	NS5A Resistance: Clinical Implications and Treatment Possibilities. <i>AIDS Reviews</i> , 2016, 18, 15-22.	1.0	4
174	Time course of serum hepatitis C virus-RNA during chronic hepatitis C treatment accurately predicts the type of response. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 241-249.	3.7	3
175	Relationship between response to interferon-alpha and function of peripheral blood mononuclear cells in chronic hepatitis C patients. <i>Digestive Diseases and Sciences</i> , 2002, 47, 2154-2162.	2.3	3
176	Gastric band cutter to remove a migrated gastric band. <i>Endoscopy</i> , 2012, 44, E40-E41.	1.8	3
177	Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0138503.	2.5	3
178	Impact of Sustained Viral Response in the Evolution of Minimal Hepatic Encephalopathy: a Prospective Pilot Study. <i>Annals of Hepatology</i> , 2019, 18, 203-208.	1.5	3
179	Impact of sustained viral response in the evolution of minimal hepatic encephalopathy: A prospective pilot study. <i>Annals of Hepatology</i> , 2019, 18, 429-433.	1.5	3
180	PS-200-The combination of HEPAmet fibrosis score and transient elastography shows a high diagnostic accuracy in predicting advanced fibrosis in NAFLD. <i>Journal of Hepatology</i> , 2019, 70, e133-e134.	3.7	3

#	ARTICLE	IF	CITATIONS
181	Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with compensated cirrhosis (AGATE Part II). Health Science Reports, 2019, 2, e92.	1.5	3
182	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis. JHEP Reports, 2021, 3, 100368.	4.9	3
183	Comparison of non-invasive fibrosis scores to predict increased liver stiffness in the general population with unknown liver disease: Searching for the primary physician's best friend. Digestive and Liver Disease, 2022, 54, 1209-1214.	0.9	3
184	1154 PEGINTERFERON ALPHA-2A ACHIEVES HIGHER EARLY VIROLOGICAL RESPONSES (RVR AND CEVR) THAN PEGINTERFERON ALPHA-2B IN CHRONIC HEPATITIS C: META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS (RCT). Journal of Hepatology, 2012, 56, S456.	3.7	2
185	Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study. Gastroenterology and Hepatology, 2014, 37, 1-8.	0.5	2
186	P219 FINE MAPPING OF THE BUTYROPHILIN GENOMICS REGION: ROLE IN HEPATITIS C VIRUS INFECTION (HCV). Journal of Hepatology, 2014, 60, S139.	3.7	2
187	P1132 PHARMACOKINETIC-RESPONSE ANALYSIS OF FALDAPREVIR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION WITH PRIOR RELAPSE. Journal of Hepatology, 2014, 60, S458-S459.	3.7	2
188	Prediction of Week 4 Virological Response in Hepatitis C for Making Decision on Triple Therapy: The Optim Study. PLoS ONE, 2015, 10, e0122613.	2.5	2
189	HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment. PLoS ONE, 2016, 11, e0168544.	2.5	2
190	Safety and Efficacy of Sofosbuvir plus Simeprevir in a Spanish Cohort of 622 Cirrhotic Patients Infected with Genotypes 1 or 4. Journal of Hepatology, 2016, 64, S831.	3.7	2
191	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). Gastroenterology and Hepatology (English Edition), 2019, 42, 579-592.	0.1	2
192	PS-022-Optimal timing of endoscopy is associated with lower 42-day mortality in variceal bleeding. Journal of Hepatology, 2019, 70, e16-e17.	3.7	2
193	Mild ast elevation as an early sign of COVID-19 severity in a multicenter Madrid cohort. Revista Espanola De Enfermedades Digestivas, 2021, 113, 780-786.	0.3	2
194	Acquired chronic hepatocerebral degeneration due to cirrhosis from non-alcoholic steatohepatitis. Revista Espanola De Enfermedades Digestivas, 2009, 101, 806-11.	0.3	2
195	Decrease in viral load at weeks 12 and 24 in patients with chronic hepatitis B treated with lamivudine or adefovir predicts virological response at week 48. Revista Espanola De Enfermedades Digestivas, 2009, 101, 763-7.	0.3	2
196	A cascade of care analysis on the elimination of hepatitis C from public hospitals in Madrid. Communications Medicine, 2022, 2, .	4.2	2
197	Consenso AEEH «Consenso sobre métodos de detección y derivación de enfermedades hepáticas prevalentes ocultas». Gastroenterology and Hepatology, 2023, 46, 236-247.	0.5	2
198	Endoscopic Ultrasonography in The Diagnosis of Aorto-esophageal Fistula. American Journal of Gastroenterology, 2000, 95, 1374-1375.	0.4	1

#	ARTICLE	IF	CITATIONS
199	Selective intestinal decontamination (SID) ameliorates the immune and hemodynamic derangement of cirrhotic patients with high levels of lysochitotriase-binding protein (LBP). <i>Journal of Hepatology</i> , 2002, 36, 44.	3.7	1
200	Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 837.	1.6	1
201	485 The improved therapeutic effects of adefovir dipivoxil in patients with HBeAg-negative chronic hepatitis B offset against its increased cost compared to lamivudine. <i>Journal of Hepatology</i> , 2006, 44, S180.	3.7	1
202	603 A SURVEY OF CHRONIC HEPATITIS B PATIENT MANAGEMENT PRACTICES IN EUROPE. <i>Journal of Hepatology</i> , 2008, 48, S225.	3.7	1
203	260 SUCCESSFUL THERAPY WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN CAUSES A SUSTAINED DECREASE IN PORTAL PRESSURE IN PATIENTS WITH CHRONIC HEPATITIS C-RELATED CIRRHOSIS. <i>Journal of Hepatology</i> , 2010, 52, S109-S110.	3.7	1
204	Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain. <i>Gastroenterology and Hepatology</i> , 2013, 36, 555-564.	0.5	1
205	Reply to: "Renal impairment and anemia during triple therapy". <i>Journal of Hepatology</i> , 2014, 60, 1100-1101.	3.7	1
206	P1041 TENOFOVIR MONOTHERAPY VERSUS LAMIVUDINE PLUS ADEFOVIR IN LAMIVUDINE-FAILURE PATIENTS RESCUED WITH LAMIVUDINE PLUS ADEFOVIR COMBINATION: INTERIM ANALYSIS OF THE TENOSIMP-B CLINICAL TRIAL. <i>Journal of Hepatology</i> , 2014, 60, S422.	3.7	1
207	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. <i>Annals of Hepatology</i> , 2015, 14, 477-486.	1.5	1
208	Efficacy and Safety of HCV-Treatment with Direct-Acting Antiviral Agents Interferon-Free, in Patients with Severe Renal Impairment in Clinical Practice. <i>Journal of Hepatology</i> , 2016, 64, S779.	3.7	1
209	Endothelial Dysfunction, Macrophage Dysfunction and Emerging Cardiovascular Risk Factors in Patients with Hepatitis C Virus Infection Characterization and Potential Reversibility with Direct Acting Antiviral Agents. <i>Journal of Hepatology</i> , 2016, 64, S823.	3.7	1
210	A pragmatic algorithm to rule out Non-alcoholic steatohepatitis in patients at risk of non-alcoholic fatty liver disease in spite of a normal ultrasound. <i>Journal of Hepatology</i> , 2017, 66, S160-S161.	3.7	1
211	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 791.	4.4	1
212	Treatment of patients with hepatitis C virus genotype 5 and 6: descriptive analysis of the Hepa-C registry. <i>Journal of Hepatology</i> , 2017, 66, S720.	3.7	1
213	FRI-439-Factor V and VIII may predict the risk of recurrent splanchnic thrombosis in patients with non-cirrhotic chronic portal vein thrombosis of local and idiopathic etiology not receiving anticoagulation. <i>Journal of Hepatology</i> , 2019, 70, e587.	3.7	1
214	SAT-424-Spleen transient elastography and suprahepatic vein dumping index can be useful to identify patients without acute and chronic response to beta-blockers. <i>Journal of Hepatology</i> , 2019, 70, e821.	3.7	1
215	IDDF2019-ABS-0136...Sofosbuvir/velpatasvir for 12 weeks is safe and effective in patients undergoing dialysis. , 2019, , .		1
216	Vascular hemichorea: case report and review. <i>Medwave</i> , 2014, 14, e5936-e5936.	0.5	1

#	ARTICLE	IF	CITATIONS
217	Editorial: clinical impact of sofosbuvir renal toxicityâ€”more light on the way. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1052-1053.	3.7	1
218	Favorable response to interferon but not to prednisone in chronic hepatitis C with non-organ specific antibodies. <i>Gastroenterology</i> , 1995, 108, A1043.	1.3	0
219	Immunoproliferative small intestinal disease: An epidemiological, clinical and immunological analysis in 28 cases. <i>Gastroenterology</i> , 1995, 108, A277.	1.3	0
220	Randomised trial of fibrin glue versus polidocanol for bleeding peptic ulcer. <i>Lancet</i> , The, 1997, 350, 1397-1398.	13.7	0
221	422 Efficacy and safety of adefovir for the treatment of patients with chronic hepatitis B (CHB) resistant to lamivudine in Spain. <i>Journal of Hepatology</i> , 2004, 40, 125.	3.7	0
222	Infliximab in Ankylosing Spondylitis Associated With Chronic Hepatitis B Infection. Role of Lamivudine Therapy. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2008, 4, 159-161.	0.3	0
223	PIN92 Patient Reported Outcomes Among Chronic Hepatitis C Patients Re-Treated with Peginterferon Alfa-2A/Ribavirin After Non-response to Peginterferon Alfa-2B/Ribavirin in Spain. <i>Value in Health</i> , 2011, 14, A282.	0.3	0
224	908 FACTORS INVOLVED IN SUSTAINED VIRAL RESPONSE (SVR) ACHIEVEMENT IN PATIENTS WITH FAVORABLE IL28B CC GENOTYPE IN HEPATITIS C. <i>Journal of Hepatology</i> , 2012, 56, S353-S354.	3.7	0
225	923 INTERACTION BETWEEN RS12979860 POLYMORPHISM OF IL28B GENE WITH BASELINE PREDICTIVE FACTORS OF RESPONSE TO TREATMENT IN PATIENTS WITH HEPATITIS C. <i>Journal of Hepatology</i> , 2012, 56, S359-S360.	3.7	0
226	Peginterferon alphaâ€”2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1705-1710.	2.8	0
227	1109 HIGH VS STANDARD DOSE OF RIBAVIRIN PLUS PEGINTERFERON-ALFA-2A IN CHRONIC HEPATITIS C, GENOTYPE 3 AND HIGH VIRAL LOAD. FINAL RESULTS OF THE DARGEN-3 STUDY. <i>Journal of Hepatology</i> , 2012, 56, S437.	3.7	0
228	Impact of Treatment Failure on the Total Cost of Triple Therapy Including Boceprevir or Telaprevir Based on the French Early Access Program (ANRS CO20-CUPLIC) Study. <i>Value in Health</i> , 2013, 16, A350.	0.3	0
229	210 SUSTAINED VIROLOGICAL RESPONSE WITH PEG-INTERFERON alfa-2a AND RIBAVIRIN DECREASES PORTAL PRESSURE GRADIENT AND PREVENTS CLINICAL DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C RELATED CIRRHOSIS. <i>Journal of Hepatology</i> , 2013, 58, S91.	3.7	0
230	894 IL28B-BASED MODEL FOR PREDICTION OF WEEK 4 VIRAL RESPONSE IN PEGINTERFERON-alfa2a + RIBAVIRIN TREATED HEPATITIS C GENOTYPE 1&4. FINAL REPORT WEEK 4 OPTIM STUDY. <i>Journal of Hepatology</i> , 2013, 58, S368.	3.7	0
231	P30: Entecavir has high efficacy and safety in Caucasian patients with chronic hepatitis B and coâ€”morbidity. <i>Journal of Viral Hepatitis</i> , 2014, 21, 38-39.	2.0	0
232	P834 NON-INVASIVE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2014, 60, S349-S350.	3.7	0
233	Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under â€œReal-Lifeâ€”Conditions. <i>Value in Health</i> , 2014, 17, A367.	0.3	0
234	P0880 : Pharmacogenomic study to predict ribavirin and protease-inhibitor-related anemia in hepatitis C. <i>Journal of Hepatology</i> , 2015, 62, S671-S672.	3.7	0

#	ARTICLE	IF	CITATIONS
235	Results of Radiofrequency Ablation in a Cohort of Cirrhotic Patients at Liver Transplantation. <i>Journal of Hepatology</i> , 2016, 64, S698.	3.7	0
236	Molecular characterization of Hepatitis C virus resistance-associated substitutions after interferon-free treatment failure by massive parallel sequencing. <i>Journal of Hepatology</i> , 2017, 66, S731.	3.7	0
237	Bacterial deoxyribonucleic is frequent in blood samples of patients with compensated cirrhosis and obesity and is associated with lack of decrease of portal pressure after an intensive lifestyle intervention. <i>Journal of Hepatology</i> , 2017, 66, S130.	3.7	0
238	Excellent efficacy but increased rate of severe adverse events in HCV-infected elderly patients undergoing interferon-free therapy. <i>Journal of Hepatology</i> , 2017, 66, S735.	3.7	0
239	Metabolic and biochemical phenotypes can distinguish different patterns of histological severity in biopsy-proven NAFLD. <i>Journal of Hepatology</i> , 2017, 66, S155-S156.	3.7	0
240	Portosystemic shunts in cirrhosis are associated to more complications and deteriorated quality of life: an international cohort study. <i>Journal of Hepatology</i> , 2017, 66, S386.	3.7	0
241	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018, 41, 597-608.	0.1	0
242	FRI-197-Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, e477-e478.	3.7	0
243	PS-023-Factors predicting survival in patients with high-risk acute variceal bleeding treated with pre-emptive (Early)-TIPS. <i>Journal of Hepatology</i> , 2019, 70, e17-e18.	3.7	0
244	SAT-079-Respiratory infection in patients with cirrhosis and acute variceal bleeding on antibiotic prophylaxis: A multicenter observational study of 2138 patients. <i>Journal of Hepatology</i> , 2019, 70, e663-e664.	3.7	0
245	THU-124-Efficacy and safety of glecaprevir/pibrentasvir for the pangenotypic treatment of chronic hepatitis C in former intravenous drug users: Subanalysis from a Spanish real-world cohort (Hepa-C). <i>Journal of Hepatology</i> , 2019, 70, e213-e214.	3.7	0
246	FRI-496-Recurrence of hepatocellular carcinoma in patients with complete response treated with direct acting antivirals in clinical practice. <i>Journal of Hepatology</i> , 2019, 70, e617.	3.7	0
247	SAT-096-Large spontaneous portosystemic shunt (SPSS) area is associated with hepatic encephalopathy and predicts mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2019, 70, e670.	3.7	0
248	Diagnosis of hepatitis C virus infection in Spain: An opportunity to improve. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2019, 37, 231-238.	0.3	0
249	IDDF2019-ABS-0134- Sofosbuvir/velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies. , 2019, , .		0
250	Optimizaci3n en el abordaje multidisciplinar del paciente con hepatitis C en la era de los antivirales de acci3n directa. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 8-13.	0.5	0
251	The Screening Guidelines for Hepatitis C Virus Infection as a milestone in the path towards hepatitis C virus elimination. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, 113, 156.	0.3	0
252	Hepatitis C reflex testing in Spain in 2019: A story of success. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2021, 39, 119-126.	0.3	0

#	ARTICLE	IF	CITATIONS
253	Quimioterapia en pacientes VHB positivos. Revista Espanola De Enfermedades Digestivas, 2012, 104, 553-553.	0.3	0
254	Ethics and relations between industry and doctors. Medwave, 2013, 13, e5765-e5765.	0.5	0
255	Successful extracorporeal shockwave lithotripsy in chronic calcified pancreatitis management. Revista Espanola De Enfermedades Digestivas, 2013, 105, 566-567.	0.3	0
256	Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Taking Concomitant Proton Pump Inhibitors: 2017 Presidential Poster Award. American Journal of Gastroenterology, 2017, 112, S545-S546.	0.4	0
257	Overall clinical and economic impact of non-alcoholic fatty liver disease. Revista Espanola De Enfermedades Digestivas, 2020, 113, 396-403.	0.3	0
258	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. Annals of Hepatology, 2015, 14, 477-86.	1.5	0
259	Interferón, ribavirina y amantadina en pacientes con hepatitis C crónica (genotipo 1) sin respuesta al tratamiento previo con interferón y ribavirina. Gastroenterología Y Hepatología, 2003, 26, 465-468.	0.5	0